Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2025)

Ptc Therapeutics (PTCT) has 9 years of Cost of Revenue data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 57.32% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $46.9 million, down 18.21%, while the annual FY2025 figure was $47.0 million, 18.09% down from the prior year.
  • Cost of Revenue reached $7.0 million in Q4 2025 per PTCT's latest filing, down from $12.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $29.1 million in Q4 2023 and bottomed at $6.5 million in Q3 2021.
  • Average Cost of Revenue over 5 years is $12.2 million, with a median of $10.9 million recorded in 2022.
  • Peak YoY movement for Cost of Revenue: skyrocketed 167.31% in 2023, then crashed 57.32% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $9.3 million in 2021, then rose by 16.79% to $10.9 million in 2022, then soared by 167.31% to $29.1 million in 2023, then crashed by 44.08% to $16.3 million in 2024, then plummeted by 57.32% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $7.0 million in Q4 2025, $12.9 million in Q1 2025, and $16.3 million in Q4 2024.